|
Tapestry Pharmaceuticals is coming unraveled. The drug ingredient and development firm founded in 1991 as NaPro Biotherapeutics primarily targeted cancer, but it has had to sell nearly all of its assets. It did hang onto a single anti-cancer compound in development, which may slow tumor growth in some types of drug-resistant solid tumors, including prostate and non-small cell lung cancers. It licensed most of its rights to the TPI 287 drug in 2008 to Archer Bioscience, although Tapestry may receive some payments if certain milestones are reached. However, as its assets shrunk and its debts mounted, the company reduced its staff, discontinued its lab operations, and ultimately, in 2009, filed for bankruptcy.
|
|
Headlines
for
Tapestry Pharmaceuticals, Inc.
| | • |
TAPESTRY PHARMACEUTICALS, INC Financials
EDGAR Online Financials
-
Thu Mar 26 | | • |
TAPESTRY PHARMACEUTICALS, INC Files SEC form 8-K, Bankruptcy or Receivership
EDGAR Online
-
Wed Mar 25 | | • |
TAPESTRY PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisiti
EDGAR Online
-
Fri Jun 6, 2008 | | • |
TAPESTRY PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisiti
EDGAR Online
-
Fri Jun 6, 2008 |
| | | Contact Information | |
Address: |
4840 Pearl East Cir., Ste. 300W
Boulder, CO 80301
| | Phone: | 303-516-8500 | | Fax: | 303-530-1296 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman:
Leonard P. Shaykin
| | • |
CEO and Director:
Gordon H. Link Jr.
| | • |
SVP and COO:
Martin M. Batt
|
|
|
